Dubai PR Network, Online Press Release from Dubai and Middle East
Healthcare(Healthcare & Medicine)
Filter PR by
Arab Health: Directions in Diabetes conference with Dr. Dr. Abdulrazzaq Al Madani

Safe and effective treatment as well as early conversations with patients are important factors in management of Type 2 Diabetes: reveal doctors at Boehringer Ingelheim’s “Directions in Diabetes - Exploring Options for Patient Care” activity during Arab Health  

Organized during the Arab Health Congress’ 3rd Middle East Diabetes Conference, the meeting gave insight into Type 2 Diabetes in the MENA region, the DPP-4 inhibitors, introduced the SGLT2 inhibitor class of diabetes therapy and presented physician results from the global IntroDia™ survey.  

• There are some 36.8 million diabetics in the MENA region, with 23.9% of them living in Saudi Arabia, 23.1% in Kuwait, 21.9% in Bahrain, 19.8% in Qatar, 19% in UAE, 16.6% in Egypt, 14.9% in Lebanon and 7.3% in Algeria. The number of people is expected to rise to 68 million by 2035.

• First insights from the global IntroDia™ study, which surveyed more than 6,700 physicians and 10,000 people with Type 2 Diabetes (T2D), including Saudi Arabia and UAE, revealed that physicians see treatment success to be equally dependent on the way people with T2D accept their condition and the efficacy of the medication.

• The DPP-4 inhibitor introduced by Boehringer Ingelheim has the unique feature of non-renal excretion and requires neither dosage monitoring nor adjustment when treating both hepatic and renal impaired T2D patients. It also delivers significant reduction in blood glucose level.

Dubai, United Arab Emirates, January 28, 2015: Type 2 Diabetes (T2D) is the most common form of diabetes often leading to chronic complications like cardiovascular disease, kidney disease, liver disease and nerve damage. Increasing incidence of diabetes is putting people at an increasing risk of developing these complications. As a result, doctors and scientific studies have been increasingly stressing the importance of adopting an effective treatment approach, which has minimal effect on organs like the kidney and heart.   

Boehringer Ingelheim, a leading pharmaceutical company, organized the “Directions in Diabetes - Exploring Options for Patient Care” educational session during the Arab Health Congress, bringing together leading endocrinologists to highlight the importance of adopting safe and effective treatment programs for patients while helping them understand their disease. The event was aimed at providing a platform for encouraging informative discussion and sharing insights into the efficacy of novel DPP-4 inhibitors as well as SGLT2 inhibitors as treatment options for people with T2D.  

“Newer classes of treatment such as DPP-4 and SGLT2 inhibitors support individualized treatment plans for patients and help in achieving better outcomes. With the introduction of newer therapies, achieving glycemic control has become easier for patients,” said Dr. Abdulrazzaq Al Madani, Consultant Endocrinologist and Physician Dubai Hospital – Dubai Health Authority and Chairman of the Emirates Diabetes Society, UAE.   

“The rising incidence of Type 2 Diabetes in the region is becoming a matter of critical concern as it not only impacts the significant increase of ensuing complications like kidney or cardiovascular disease, but also impacts society with rising expenditure on treatments. People have accepted it as a lifestyle disease without knowledge of the ensuing life-threatening complications which need to be controlled. One of our priorities is to help patients understand their disease and take precautions,” said Dr. Saud Al Sifri, Chairman of Endocrinology and Diabetes Department at Al Hada Armed Forces Hospitals, Saudi Arabia.   

DPP-4 inhibitors act by inhibiting the degradation of incretion hormones, thereby increasing insulin release in a glucose-dependent manner and decreasing the levels of circulating glucagon. Boehringer Ingelheim’s DDP-4 inhibitor, introduced for the treatment of adults with T2D, is primarily excreted through the bile and the gut rather than through renal elimination. This allows the use of the medication even in patients with failing liver or kidney function.

SGLT2 inhibition reduces reabsorption of glucose into the bloodstream, allowing excess glucose to pass through the urine, leading to urinary glucose excretion. It has been shown to be an effective way of lowering blood glucose in the management of T2D with a positive effect on body weight and blood pressure.

Boehringer Ingelheim also introduced the first physician results from IntroDia™, a global survey about early conversations in T2D, which will include insights from more than 10,000 patients with T2D and more than 6,700 treating physicians, across 26 countries. From the Middle East, 60 physicians from Saudi Arabia and UAE participated in the survey. The aim of the survey is to understand how physicians and people with T2D conduct early conversations and the challenges faced during these conversations. Being diagnosed with T2D can be a challenging and emotional period, which many people find overwhelming. A person is faced with a range of challenges, including taking new medication and making lifestyle changes, which can trigger psychological distress.

“It is one of our constant efforts to understand the treatment challenges being faced by doctors and patients and the need for advanced medication, which can help people achieve better outcomes with minimal effects on their lives,” said Karim El Alaoui, Managing Director, Middle East, Turkey and Africa, Boehringer Ingelheim.  

Some of the highlights include:

• Over three quarters of the surveyed physicians (76-100% across 26 countries) agreed that conversations at diagnosis impact the way people with T2D accept their condition, as well as their treatment adherence.

• The challenges most commonly reported by physicians during diagnosis conversations were that patients do not always keep up with the required changes, returning to old habits. Physicians also reported not having enough time to carry out important conversations with patients. • Physicians reported that treatment success is dependent on both behavioral change and the efficacy of medication in approximately equal measures which resulted as a 50-50% from the survey.

• Most physicians surveyed (92%) also indicated they would like tools to help people with T2D sustain behavioral change

Posted by : Dubai PR Network Editorial Team
Viewed 20685 times
PR Category : Healthcare & Medicine
Posted on : Wednesday, January 28, 2015  4:37:00 PM UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of
Previous Story : Sheikh Khalifa Medical City Organises a Public Health Talk a...
Next Story : Swiss International Scientific School Dubai to open in Dubai...
Email this article Print this article

Share this article with your friends and followers
Back to Section Home

Related Stories

Most Viewed Press Release posted in the last 7 days
Filorga Launches FLASH-NUDE Collection [16781-Views]
The Rado DiaMaster Petite Seconde Automatic COSC The Rado watch at the top of the precisio... [15201-Views]
Maintain Healthy Skin Year Round [11980-Views]
PopSockets launches a new collection with crystals from Swarovski, the must-have accessory... [11779-Views]
Free gold coins at Malabar Gold & Diamonds Festival [9723-Views]
MIDO Baroncelli Lady Day & Night collection [9595-Views]
24 Karat Gold Elixir by Mehrunisa Launches in the UAE Beauty Market [8644-Views]
Interview with Asil Attar, CEO of Al Yasra Fashion [7576-Views]
Holiday Gifting Made Easy with Wet n Wild Beauty Specials [7186-Views]
Get Ready for Party Season with Lottie's new make-up hits [7052-Views]
GAZOO Racing Wins Australia Rally at FIA World Rally Championship [6826-Views]
Golden Mile Galleria's ‘A Cultural Flair' attracts hundreds of art lovers to Palm Jumeirah [6747-Views]
Festive Gift Sets from Bubble T [6673-Views]
Tissot PR100 Lady Sport – Chic Glamourous Festive Season [6631-Views]
Winter wool Christmas must- haves [6198-Views]
Time For Enchanting Moments [5978-Views]
Samsung Galaxy A9 – Designed to capture the world in its fullest [5612-Views]
New 1948 Seamaster Watches Join the Ranks' [5435-Views]
Michael Kors Collection Transeason 2019 Press Presentation [5264-Views]
Chic and Stylish Wraps with a 3 in 1 effortless concept [5191-Views]
Els Back for the 30th Omega Dubai Desert Classic Aiming for a Record Fourth Victory [4691-Views]
9th Edition of China Homelife Exhibition to Have Over 3000 Exhibitors Across Business Sect... [4673-Views]
Tissot PR100 Lady Sport – Chic Sporty yet Feminine [4612-Views]
New Menu alert: Moombai & Co. launches exciting and delicious food items to its menu [4514-Views]
Five-Star Euro NCAP for Jaguar's Electric I-PACE [4337-Views]
RSS Facebook Twitter LinkedDin
Top Sections
Top Stories